<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exact Sciences 2024 Revenue by Test</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #e0f7fa 0%, #b2ebf2 100%);
            padding: 40px 20px;
            min-height: 100vh;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background: white;
            border-radius: 16px;
            box-shadow: 0 8px 32px rgba(0, 188, 212, 0.2);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #00bcd4 0%, #26c6da 100%);
            color: white;
            padding: 40px;
            text-align: center;
        }
        
        .header h1 {
            font-size: 32px;
            margin-bottom: 10px;
            font-weight: 600;
        }
        
        .header p {
            font-size: 18px;
            opacity: 0.95;
        }
        
        .content {
            padding: 40px;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
            margin-bottom: 30px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.08);
        }
        
        thead {
            background: linear-gradient(135deg, #80deea 0%, #4dd0e1 100%);
        }
        
        th {
            padding: 18px 16px;
            text-align: left;
            font-weight: 600;
            color: #006064;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        tbody tr {
            border-bottom: 1px solid #e0f7fa;
            transition: all 0.3s ease;
        }
        
        tbody tr:nth-child(odd) {
            background-color: #e0f7fa;
        }
        
        tbody tr:nth-child(even) {
            background-color: white;
        }
        
        tbody tr:hover {
            background-color: #b2ebf2;
            transform: scale(1.01);
            box-shadow: 0 2px 8px rgba(0, 188, 212, 0.2);
        }
        
        td {
            padding: 16px;
            color: #00363a;
            font-size: 15px;
        }
        
        .test-name {
            font-weight: 600;
            color: #006064;
        }
        
        .revenue {
            font-weight: 700;
            color: #00838f;
            font-size: 16px;
        }
        
        .badge {
            display: inline-block;
            padding: 6px 12px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .badge-fda {
            background: linear-gradient(135deg, #81c784 0%, #66bb6a 100%);
            color: white;
        }
        
        .badge-ldt {
            background: linear-gradient(135deg, #4dd0e1 0%, #26c6da 100%);
            color: white;
        }
        
        .badge-launch {
            background: linear-gradient(135deg, #ffb74d 0%, #ffa726 100%);
            color: white;
        }
        
        .summary-box {
            background: linear-gradient(135deg, #b2ebf2 0%, #80deea 100%);
            border-radius: 12px;
            padding: 30px;
            margin-top: 20px;
        }
        
        .summary-title {
            font-size: 24px;
            font-weight: 600;
            color: #006064;
            margin-bottom: 20px;
        }
        
        .summary-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
        }
        
        .summary-card {
            background: white;
            padding: 20px;
            border-radius: 8px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.08);
        }
        
        .summary-label {
            font-size: 13px;
            color: #00838f;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 8px;
            font-weight: 600;
        }
        
        .summary-value {
            font-size: 28px;
            font-weight: 700;
            color: #006064;
        }
        
        .note {
            background: #e0f7fa;
            border-left: 4px solid #00bcd4;
            padding: 20px;
            margin-top: 30px;
            border-radius: 4px;
        }
        
        .note p {
            color: #00363a;
            line-height: 1.6;
            margin-bottom: 10px;
        }
        
        .note p:last-child {
            margin-bottom: 0;
        }
        
        @media (max-width: 768px) {
            .header h1 {
                font-size: 24px;
            }
            
            .content {
                padding: 20px;
            }
            
            table {
                font-size: 13px;
            }
            
            th, td {
                padding: 12px 8px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>Exact Sciences 2024 Revenue by Test</h1>
            <p>Comprehensive breakdown of diagnostic test earnings</p>
        </div>
        
        <div class="content">
            <table>
                <thead>
                    <tr>
                        <th>Test Name</th>
                        <th>2024 Revenue</th>
                        <th>Status</th>
                        <th>Segment</th>
                        <th>Additional Info</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td class="test-name">Cologuard</td>
                        <td class="revenue">~$2.0 billion</td>
                        <td><span class="badge badge-fda">FDA Approved</span></td>
                        <td>Screening</td>
                        <td>Part of 4.6M total tests across portfolio</td>
                    </tr>
                    <tr>
                        <td class="test-name">Oncotype DX</td>
                        <td class="revenue">~$600+ million</td>
                        <td><span class="badge badge-ldt">LDT</span></td>
                        <td>Precision Oncology</td>
                        <td>230,000 patients globally</td>
                    </tr>
                    <tr>
                        <td class="test-name">PreventionGenetics</td>
                        <td class="revenue">~$100 million</td>
                        <td><span class="badge badge-ldt">LDT</span></td>
                        <td>Screening</td>
                        <td>Germline genetic testing</td>
                    </tr>
                    <tr>
                        <td class="test-name">OncoExTra</td>
                        <td class="revenue">~$30-40 million</td>
                        <td><span class="badge badge-ldt">LDT</span></td>
                        <td>Precision Oncology</td>
                        <td>Launched Feb 2023</td>
                    </tr>
                    <tr>
                        <td class="test-name">Riskguard</td>
                        <td class="revenue">Not disclosed</td>
                        <td><span class="badge badge-ldt">LDT</span></td>
                        <td>Not specified</td>
                        <td>Revenue not broken out</td>
                    </tr>
                    <tr>
                        <td class="test-name">Cologuard Plus</td>
                        <td class="revenue">$0</td>
                        <td><span class="badge badge-launch">2025 Launch</span></td>
                        <td>Screening</td>
                        <td>Launched Q1 2025</td>
                    </tr>
                    <tr>
                        <td class="test-name">Oncodetect</td>
                        <td class="revenue">$0</td>
                        <td><span class="badge badge-launch">2025 Launch</span></td>
                        <td>Precision Oncology</td>
                        <td>Launched April 2025</td>
                    </tr>
                    <tr>
                        <td class="test-name">Cancerguard</td>
                        <td class="revenue">$0</td>
                        <td><span class="badge badge-launch">2025 Launch</span></td>
                        <td>Screening</td>
                        <td>Launched Sept 2025</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="summary-box">
                <div class="summary-title">2024 Financial Summary</div>
                <div class="summary-grid">
                    <div class="summary-card">
                        <div class="summary-label">Total Revenue</div>
                        <div class="summary-value">$2.759B</div>
                    </div>
                    <div class="summary-card">
                        <div class="summary-label">Screening Segment</div>
                        <div class="summary-value">$2.10B</div>
                        <div style="font-size: 14px; color: #00838f; margin-top: 5px;">76.12% of total</div>
                    </div>
                    <div class="summary-card">
                        <div class="summary-label">Precision Oncology</div>
                        <div class="summary-value">$655M</div>
                        <div style="font-size: 14px; color: #00838f; margin-top: 5px;">23.7% of total</div>
                    </div>
                    <div class="summary-card">
                        <div class="summary-label">Year-over-Year Growth</div>
                        <div class="summary-value">11%</div>
                        <div style="font-size: 14px; color: #00838f; margin-top: 5px;">Core growth</div>
                    </div>
                </div>
            </div>
            
            <div class="note">
                <p><strong>Note:</strong> Exact Sciences does not publicly disclose individual product-level revenue. The figures above are estimates based on percentages and context provided in company documents.</p>
                <p><strong>Test Volume:</strong> The 4.6 million figure represents total tests across Exact Sciences' entire cancer testing portfolio in 2024, including Cologuard, Oncotype DX, PreventionGenetics tests, OncoExTra, and other diagnostics. Individual product-level test volumes are not disclosed.</p>
                <p><strong>FDA Status:</strong> Only Cologuard and Cologuard Plus have FDA approval (PMA pathway). All other tests operate as Laboratory Developed Tests (LDTs) under CLIA regulations without FDA approval, with one exception: PreventionGenetics received FDA approval for its POMC/PCSK1/LEPR companion diagnostic test (Class II device) on June 30, 2022.</p>
                <p><strong>2025 Launches:</strong> Three major products launched in 2025 and therefore had no 2024 revenue contribution.</p>
            </div>
        </div>
    </div>
</body>
</html>